CANTON, Mass., March 16, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. COLL today announced that management will present at the following investor conferences in March:
- The Oppenheimer & Company 28th Annual Healthcare Conference on Wednesday, March 21st at 9:10 a.m. ET in New York City
- The Needham 17th Annual Healthcare Conference on Wednesday, March 28th at 10:30 a.m. ET in New York City
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium's first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
adasalla@collegiumpharma.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
